Evidence map›Paper›PMID 42816626›Full record

ArticleNature2026

Type 2 immune history trains lung macrophages for viral disease tolerance.

Payal Damani-Yokota, Yavor Yordanov, Eduardo D Bernier, Chaitra Sreenivasaiah, Alireza Khodadadi-Jamayran, Matthias C Kugler, Stephen T Yeung, Stacey Bartlett, Valeria Mezzano, Eric Bartnicki and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Payal Damani-YokotaDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY, USA.
Yavor YordanovDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Eduardo D BernierDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY, USA.
Chaitra SreenivasaiahApplied Bioinformatics Laboratories, Office of Science and Research, New York University School of Medicine, New York, NY, USA.
Alireza Khodadadi-JamayranApplied Bioinformatics Laboratories, Office of Science and Research, New York University School of Medicine, New York, NY, USA.
Matthias C KuglerDivision of Pulmonary and Critical Care Medicine, New York University, New York, NY, USA.ORCID http://orcid.org/0000-0002-8587-6129
Stephen T YeungDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-9710-5567
Stacey BartlettDepartment of Medicine/Division of Infectious Diseases and Immunology, New York University Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-7352-2681
Valeria MezzanoDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.
Eric BartnickiDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0001-8959-6282
Mingjun LiuDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.
Fei ChenCenter for Immunity and Inflammation, New Jersey Medical School, Rutgers-The State University of New Jersey, Newark, NJ, USA.
William C GauseCenter for Immunity and Inflammation, New Jersey Medical School, Rutgers-The State University of New Jersey, Newark, NJ, USA.ORCID http://orcid.org/0000-0002-8062-4790
Aristotelis TsirigosApplied Bioinformatics Laboratories, Office of Science and Research, New York University School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-7512-8477
Iannis AifantisDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0001-6857-1035
Mila B OrtigozaDepartment of Medicine/Division of Infectious Diseases and Immunology, New York University Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-9428-1469
Bettina NadorpDivision of Precision Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0003-1974-8425
Musa M MhlangaDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0003-1381-3409
Kamal M KhannaDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY, USA. Kamal.khanna@nyulangone.org.ORCID http://orcid.org/0000-0002-9328-3817

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe respiratory viral disease varies widely among individuals and often reflects immunopathology rather than inadequate pathogen control, suggesting that previous immune history can prime the lungs towards disease tolerance. Here we show that nerve- and airway-associated macrophages (NAMs), a subset of interstitial macrophages, expand ephemerally after type 2 inflammation induced by Nippostrongylus brasiliensis. We therefore hypothesized that NAMs acquire epigenetically imprinted trained immunity and tested this using a heterologous challenge model in which mice that were previously infected with N. brasiliensis were challenged 4-6 weeks later with lethal H1N1 influenza. All of the N. brasiliensis-conditioned mice survived, whereas all of the unconditioned controls succumbed by days 5-6. Protection occurred without reduced viral burden or enhanced T cell responses, instead tracking with reduced immunopathology, amplified type 2 cues, increased efferocytosis and accelerated tissue repair. Using NAM-DTR mice, we show that conditioned NAMs are necessary and sufficient for protection: depletion or replacement with unconditioned NAMs abrogated survival, whereas adoptive transfer of conditioned NAMs conferred tolerance without enhancing viral clearance. Genomic analyses implicated an IL-4-STAT6-PPARγ and ARG1 chromatin program that imprints a pro-resolving and reparative NAM state driving tissue repair, type 2 immunity and efferocytosis during lethal respiratory viral infections. Finally, meta-analysis of human lung single-cell atlases from cohorts of healthy individuals and individuals with IPF and COPD revealed context-dependent NAM-like repair programs. These findings establish local trained immunity in lung-resident macrophages as a mechanism of disease tolerance and a therapeutic entry point for severe inflammatory respiratory infections.

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.